Specialist, QC Microbiology, Cell Therapy at Bristol-Myers Squibb

Leiden, South Holland, Netherlands

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Ability to accurately and completely understand, follow, interpret and apply Global Regulatory and cGMP requirements
Knowledge of LIMS, ELN and laboratory data analysis systems preferred
Problem-solving ability/mentality, technically adept and logical
Ability to communicate effectively with peers, department management and cross-functional peers
Experience with writing technical documents preferred
Ability to work in a fast-paced team environment, meet deadlines, and prioritize work

Responsibilities

Perform routine testing of in-process, final product and stability samples
Perform environmental/facilities monitoring and microbiological testing
May perform testing for method transfer/verification/validation
Perform data verification, data review and review of GMP documentation for general methods
May perform document revision, project, CAPA and deviation/investigation related tasks and/or continuous improvement efforts
Train analysts on general job duties
Perform other tasks as assigned

Skills

Microbiology

Quality Control

Cell Therapy

GMP

Manufacturing

Biotech

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free